UOC
OPTR

UBS O'Connor’s OPTIMER PHARMACEUTICALS, INC. COM STK OPTR Stock Holding History

UBS O'Connor’s Portfolio OPTR Stock Details OPTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-60,000
Closed -$868K – 651
2013
Q2 		$868K Buy
+60,000
New +$874K 0.02% 386

Other funds holding OPTR

WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Alpine Associates Advisors Englewood Cliffs, New Jersey $158M AUM 48.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

UBS O'Connor's OPTR Position: Q3 2013 in Review

UBS O'Connor sold out of OPTIMER PHARMACEUTICALS, INC. COM STK (OPTR) in Q3 2013, closing a stake of 60,000 shares — an estimated $868K sold.

UBS O'Connor first reported a position in OPTR in Q2 2013 and held it in 1 quarter. The position peaked at $868K in Q2 2013. 104 funds tracked by Wall St. Rank hold OPTR as of Q3 2013.

  • UBS O'Connor reported no remaining OPTIMER PHARMACEUTICALS, INC. COM STK position as of Q3 2013 after selling out during the quarter.
  • UBS O'Connor sold 60,000 OPTIMER PHARMACEUTICALS, INC. COM STK shares in Q3 2013, an estimated $868K.
  • UBS O'Connor first reported a position in OPTIMER PHARMACEUTICALS, INC. COM STK in Q2 2013 and held it in 1 quarter.
  • UBS O'Connor's OPTIMER PHARMACEUTICALS, INC. COM STK position peaked at $868K in Q2 2013.
  • 104 funds tracked by Wall St. Rank held OPTIMER PHARMACEUTICALS, INC. COM STK as of Q3 2013.

Based on UBS O'Connor's 13F filing for Q3 2013, filed 14 Nov 2013.